Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jul;64(1):169–173. doi: 10.1038/bjc.1991.263

The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.

A D Pearson 1, H A Amineddine 1, M Yule 1, S Mills 1, D R Long 1, A W Craft 1, J M Chessells 1
PMCID: PMC1977331  PMID: 1854617

Abstract

Sequential methotrexate (Mtx) absorption studies were undertaken in 127 children undergoing treatment for childhood non-T acute lymphoblastic leukaemia (ALL) to determine whether serum drug concentration, clearance and dosage affect event free survival (EFS). Higher serum concentration and area under the plasma concentration curve (AUC) were not associated with an improved EFS. Methotrexate clearance was not found to be of prognostic significance. Patients who tolerated only low 6-mercaptopurine (6-MP) doses because of neutropaenia and those who randomly were prescribed higher doses of Mtx had a lower rate of leukaemia relapse after the completion of therapy. This suggests that the use of maintenance therapy in maximally tolerated doses may be associated with an increased survival in childhood ALL.

Full text

PDF
169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balis F. M., Savitch J. L., Bleyer W. A. Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983 May;43(5):2342–2345. [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  3. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  4. Chabner B. A., Allegra C. J., Curt G. A., Clendeninn N. J., Baram J., Koizumi S., Drake J. C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907–912. doi: 10.1172/JCI112088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chessells J. M., Leiper A. D., Tiedemann K., Hardisty R. M., Richards S. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia. Arch Dis Child. 1987 Feb;62(2):172–176. doi: 10.1136/adc.62.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Evans W. E., Crom W. R., Abromowitch M., Dodge R., Look A. T., Bowman W. P., George S. L., Pui C. H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986 Feb 20;314(8):471–477. doi: 10.1056/NEJM198602203140803. [DOI] [PubMed] [Google Scholar]
  7. Evans W. E., Crom W. R., Stewart C. F., Bowman W. P., Chen C. H., Abromowitch M., Simone J. V. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet. 1984 Feb 18;1(8373):359–362. doi: 10.1016/s0140-6736(84)90411-2. [DOI] [PubMed] [Google Scholar]
  8. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  9. Kearney P. J., Light P. A., Preece A., Mott M. G. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1979;3(2):117–120. doi: 10.1007/BF00254982. [DOI] [PubMed] [Google Scholar]
  10. Lennard L., Lilleyman J. S., Van Loon J., Weinshilboum R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990 Jul 28;336(8709):225–229. doi: 10.1016/0140-6736(90)91745-v. [DOI] [PubMed] [Google Scholar]
  11. Lennard L., Rees C. A., Lilleyman J. S., Maddocks J. L. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983 Oct;16(4):359–363. doi: 10.1111/j.1365-2125.1983.tb02178.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pearson A. D., Mills S., Amineddine H. A., Long D. R., Craft A. W., Chessells J. M. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1987;20(3):243–247. doi: 10.1007/BF00570494. [DOI] [PubMed] [Google Scholar]
  13. Pinkel D., Hernandez K., Borella L., Holton C., Aur R., Samoy G., Pratt C. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. 1971 Feb;27(2):247–256. doi: 10.1002/1097-0142(197102)27:2<247::aid-cncr2820270202>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  14. Pinkerton C. R., Welshman S. G., Dempsey S. I., Bridges J. M., Glasgow J. F. Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia. Br J Cancer. 1980 Oct;42(4):613–615. doi: 10.1038/bjc.1980.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Smith S. D., Rosen D., Trueworthy R. C., Lowman J. T. A reliable method for evaluating drug compliance in children with cancer. Cancer. 1979 Jan;43(1):169–173. doi: 10.1002/1097-0142(197901)43:1<169::aid-cncr2820430125>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  16. Whitehead V. M., Rosenblatt D. S., Vuchich M. J., Shuster J. J., Witte A., Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood. 1990 Jul 1;76(1):44–49. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES